Your session is about to expire
← Back to Search
Efruxifermin for NASH with Cirrhosis
Study Summary
This trial is testing a new drug for people with a certain kind of liver disease. The disease is called NASH, and it's serious enough that it can cause cirrhosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 110 Patients • NCT03976401Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have Type 2 diabetes or at least two symptoms of metabolic syndrome.I have cirrhosis confirmed by a liver biopsy.I have cirrhosis from NASH confirmed by a biopsy.My liver fibrosis is at stage 1, 2, or 3.I have been diagnosed with type 2 diabetes.I have been using a GLP-1R agonist medication for at least 90 days.I have Type 1 diabetes or my Type 2 diabetes is not under control.I have lost more than 10% of my weight in the last 3 months or since my liver biopsy.I have lost more than 5% of my weight in the last 3 months.I am between 18 and 75 years old, not pregnant, and not breastfeeding.I have Type 2 diabetes or at least two symptoms of metabolic syndrome.I have cirrhosis from NASH confirmed by a biopsy.I am between 18 and 75 years old, not pregnant, and not breastfeeding.
- Group 1: Placebo (Cohort D)
- Group 2: EFX 28 mg (Main Study)
- Group 3: EFX 50 mg (Cohort D)
- Group 4: EFX 50 mg (Main Study)
- Group 5: Placebo (Main Study)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the harmful effects that have been associated with EFX?
"EFX's safety was given a score of 2 because, although there is some data supporting its safety, there is no evidence that it is an effective medication."
Who meets the requirements to sign up for this experiment?
"This study is recruiting 200 patients that have non alcoholic steatohepatitis (nash) and are between 18-75 years old."
In how many places is this research being conducted?
"Presently, this clinical trial is operational in 51 locations. If you are considering enrolling in the trial, be mindful of the fact that some travel may be required and try to pick a location near to you from the list of sites."
Does this research project have an age limit for participants?
"Individuals aged 18 to 75 who meet the other inclusion criteria may participate in this clinical trial. There are 24 trials for people under 18 and 203 trials for senior citizens."
How many people are receiving care through this clinical trial?
"The clinical trial is currently recruiting patients, as reflected on the website clinicaltrials.gov. The study was posted on 7/30/2021 and last edited on 9/8/2022; at present, they are looking for 200 participants from 51 different sites."
Are people with the required health qualifications able to participate in this trial at this time?
"That is accurate. The clinical trial mentioned is, as of now, looking for participants. The original posting was on 7/30/2021 and the most recent update was 9/8/2022. A total of 200 patients are needed to be enrolled between 51 different sites."
What are the team's objectives with this research?
"The primary goal of this study, which will be conducted over the course of 36 weeks, is to observe changes in fibrosis with no worsening steatohepatitis using the NASH CRN system. Additionally, this trial hopes to secondary objectives including observing the resolution of NASH with no worsening of fibrosis (determined by the NASH CRN system), Changes from baseline in lipoproteins, and change from baseline of non-invasive markers of fibrosis."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger